Metabolic HealthFDA Approves Baxfendy, a New Aldosterone Synthase Inhibitor for Hypertension
The FDA approved Baxfendy (baxdrostat) on May 15, 2026, as an add-on treatment for hypertension in adults who need additional blood pressure control beyond existing medications. Baxdrostat works by inhibiting aldosterone synthase, the enzyme responsible for producing aldosterone — a hormone that raises blood pressure by causing the kidneys to retain sodium and water. This marks a genuinely new mechanism of action in hypertension treatment, a field that has seen few novel drug classes in recent decades. The approval is especially relevant for patients with resistant or difficult-to-control hypertension, where aldosterone excess is often a contributing factor. Clinicians managing metabolic syndrome, obesity-related hypertension, or primary aldosteronism may find this a valuable new tool in their therapeutic arsenal.
